

Papers

Van Gestel A, Webers CAB, Severens JL, Beckers HJM, Jansonius NM, Hendrikse F, Schouten JSAG. The long term outcomes of four alternative treatment strategies for primary open-angle glaucoma. *Acta Ophthalmologica Scandinavica*, 2012; 90(1): 20-31.

Van Gestel A, Grutters JP, Schouten JAG, Webers CAB, Beckers HJM, Joore MA, Severens JL. The role of the expected value of individualized care in cost-effectiveness analysis and decision making. *Value in Health*, 2012; 15(1): 13-21.

Van Gestel A, Webers CAB, Beckers HJM, Van Dongen MCJM, Severens JL, Hendrikse F, Schouten JSAG. The relationship between visual field loss in glaucoma and health-related quality-of-life. *Eye*, 2010, 24(12): 1759-1769.

Van Gestel A, Severens J, Webers C, Beckers H, Jansonius N, Schouten J. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. *Value Health* 2010;13(4):358-67.

Heeg B, **Van Gestel A**, Van Hout B, Olsen J, Haghfelt TH. Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark. *Ugeskrift for Laeger* 2006;168(35):2911-5.

Moller HJ, Laux G, Naber D, Gastpar MT, Klosterkötter J, Schmauss M, Heeg B, **Van Gestel A**, Van Hout B, Mehnert A. Costs and effects of long-acting risperidone in comparison to oral atypical and conventional depot formulations for the treatment of patients with schizophrenia in Germany. *Psychopharmakotherapie* 2005;12(5):183-92.

Bakker J, Levi M, Van Hout BA, **Van Gestel A**. Sepsis, a complicated syndrome with major medical and social consequences. *Ned Tijdschr Geneesk* 2004; 148(20): 975-978

Van Gestel A, Bakker J, Veraart C, Van Hout BA. Prevalence and incidence of severe sepsis in Dutch intensive care units. *Critical Care* 2004; 8(4): R153-R162

Zuideveld KP, **Van Gestel A**, Peletier LA, Van der Graaf PH, Danhof M. Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT_{1A} receptor agonist flesinoxan. *Eur J Pharmacol*, 2002; 455: 53-54.

Reports

Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Kosten-effectiviteit van de behandeling en monitoring van oculaire hypertensie en glaucoom. Eindverslag ZonMW, Dossiernummer 94504451, mei 2008.

Van Oostenbruggen MF, Tergau AC, **Van Gestel A**, Van Hout BA, Rutten FFH. Kies Keurig; Een verkennend onderzoek naar de optimalisatie van het besluitvormingsproces over de vergoeding van extramurale geneesmiddelen. PharMerit, Capelle Aan Den IJssel 2002.

Presentations

Van Gestel A, Grutters J, Joore M, Severens J, Schouten J, Webers C, Beckers H. The role of the expected value of individualized care in cost-effectiveness analyses and decision making. International Health Economics Associations (iHEA) conference, July 2011, Toronto, Canada. Oral presentation in the organized session "Every person is unique; heterogeneity in economic evaluation and decision-making".

Van Gestel A, Grutters J, Joore M, Severens J, Schouten J, Webers C, Beckers H. Exploring the role of the expected value of individualized care in cost-effectiveness analyses and decision making. Lowlands Health Economists Study Group conference. May 27-28 2010, Egmond aan Zee, the Netherlands.

Van Gestel A, Schouten J, Webers C, Beckers H, Jansonius N, Severens J. Construction and validation of a decision analytic model for ocular hypertension and glaucoma. European Glaucoma Society conference, Health Economics Special interest group session. 17 September 2010, Madrid, Spain. Oral presentation and discussion.

Van Gestel A, Schouten J, Webers C, Beckers H, Jansonius N, Severens J. Validatie van een OHT-POAG ziekteprogressie model. Nederlands Oogheelkundig Gezelschap, 26 March 2009, Groningen, the Netherlands. Oral presentation.

Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. A novel approach to establish at which IOP to start treatment for ocular hypertension. World Glaucoma Congress, 8-11 July 2009, Boston, USA. Poster presentation.

Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Does every bit of visual field loss count? World Glaucoma Congress, 8-11 July 2009, Boston, USA. Poster presentation.

Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Kwaliteit van leven bij oculaire hypertensie en glaucoom. Nederlands Oogheelkundig Gezelschap, 3 April 2008, Maastricht, the Netherlands. Oral presentation.

Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Risk of blindness in patients with ocular hypertension. Joint Congress of SOE/AAO, 9-12 June 2007, Vienna, Austria. Rapid Fire Presentation

Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Primary open-angle glaucoma: the impact on quality-of-life and utility. Joint Congress of SOE/AAO, 9-12 June 2007, Vienna, Austria. Poster presentation and oral presentation at Best Poster Session.

Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Een discrete event model voor oculaire hypertensie en glaucoom: concept, opbouw en eerste resultaten. Nederlandse Glaucoom Groep, 11 November 2007, Utrecht, the Netherlands.

Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Health related quality of life and utility in Dutch glaucoma patients. European Conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 29-31 October 2006, Copenhagen, Denmark. Poster presentation.